Skip to main content
Caplight Logo









Innovative Cellular Therapeutics

Innovative Cellular Therapeutics

Private
Rockville, MarylandHealthcare & Life Scienceshttps://www.ictbio.com/

Last Round

Series C

Sep 6, 2021

Total Funding Raised

$96.9M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Innovative Cellular Therapeutics is a biotechnology company specializing in the development of chimeric antigen receptor T cell products aimed at treating blood cancers and solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T therapycell therapysolid tumor treatmentimmunotherapyCoupledCARKIR-CARcancer immunotherapyclinical-stage biotechcellular engineeringoncology researchnext-gen CAR-Tbiotech startupclinical trialsdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Innovative Cellular Therapeutics Comparables

Compare Innovative Cellular Therapeutics with similar companies based on industry and business-model similarity.

Innovative Cellular Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Triumvira Immunologics
85%
A2 Biotherapeutics
85%
Inceptor Bio
85%

Innovative Cellular Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CSep 6, 2021
Series B ExtensionDec 18, 2019
Series BApr 24, 2018
Series AOct 1, 2016

Key People

Founding team and executive leadership

Larry Xiao

Chief Executive Officer

Executive Team

victor lu

CTO & Head of Quality and Compliance

Executive Team

Innovative Cellular Therapeutics Investors

Notable investors and investment history

Innovative Cellular Therapeutics investors
InvestorRounds
CDH InvestmentsSeries A, Series C
LongHash VenturesSeries B Extension
Linghang VenturesSeries B Extension
CDH VGCSeries C
Shenzhen GTJA Investment GroupSeries B
Witruth CapitalSeries B
Volcanics VentureSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 41% to 2.1K.

  • Nov 11, 2025

    Lyell Immunopharma acquired rights to LYL273 for cancer treatment.

Innovative Cellular Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Innovative Cellular Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Innovative Cellular Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersRockville, Maryland
Employee Range15
Year Founded2009
Last FundingSep 6, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?